Company Performance - WORK Medical Technology Group Ltd. experienced a significant price drop of approximately 88% to $0.10, yet remains focused on developing AI-driven medical products through a strategic partnership with the Wuxi Branch of Ruijin Hospital [1][7] - BT Brands, Inc. (BTBDW) saw a 34% decrease in stock price to $0.16, affected by consumer cyclical trends in the quick-service restaurant sector [2][7] - Fitness Champs Holdings Limited (FCHL) faced a 33% decline to $0.71, following its initial public offering where it offered 3.75 million shares at $4.00 each, continuing to contribute to sports education and merchandise sales [3][7] - SAIHEAT Limited (SAIHW) experienced a 32% decline to $0.18, focusing on liquid-cooling data centers and high-performance servers, emphasizing sustainable solutions in the technology sector [4][7] - Zhengye Biotechnology Holding Limited (ZYBT) saw a 28% decrease to $5.01, with a focus on veterinary vaccines and a transformational fiscal year 2024 aimed at diversifying its customer base for long-term growth [5] Industry Dynamics - The market movements reflect the impact of industry dynamics and consumer behavior on company performance, highlighting the need for adaptation to market trends and strategic partnerships for growth [6]

Core Viewpoint - Zhengye Biotechnology Holding Limited has received a Delinquency Letter from NASDAQ due to non-compliance with listing requirements, specifically for failing to file its annual report on Form 20-F for the fiscal year ended December 31, 2024 [1][2]. Group 1: Compliance and Regulatory Actions - The Company has 60 calendar days from the date of the Delinquency Letter to submit a Compliance Plan to regain compliance with NASDAQ Listing Rules [2]. - If the Compliance Plan is accepted, NASDAQ may grant an extension of up to 180 calendar days from the filing due date, potentially until November 11, 2025, for the Company to regain compliance [2]. - The Delinquency Letter does not have an immediate impact on the listing of the Company's ordinary shares on the Nasdaq Capital Market [3]. Group 2: Company Overview - Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in China [4]. - The operating entity has developed 44 veterinary vaccines for various animals, including swine, cattle, goats, sheep, poultry, and dogs, and its products are available in 28 provincial regions across China and exported to countries like Vietnam, Pakistan, and Egypt [4]. - The Company operates three GMP veterinary vaccine production floors with 13 GMP vaccine production lines and employs 49 individuals with over a decade of experience in the veterinary vaccine industry [4].